AFP and neoplasm: Furthermore, regarding the association between TACE and sorafenib combination and reduced overall mortality risk, statistical significance was reached in some subgroups (age >60 years, male sex, BCLC stage A or B, Child–Pugh class A5, tumor size >3 cm, AFP ≤200 ng/mL, and tumor response CR and PR).